Search results for "origin"

showing 10 items of 4356 documents

Randomised double-blind placebo-controlled intervention study on the nutritional efficacy of a food for special medical purposes (FSMP) and a dietary…

2019

ObjectiveTo assess whether the symptoms of veisalgia can be reduced by intense water supply and the intake of antioxidative supplements and plant extracts.MethodsWe performed the world’s largest randomised double-blind placebo-controlled intervention study (214 participants) on the efficacy of a food for special medical purposes (FSMP) against veisalgia symptoms. We analysed the effectiveness of: (1) an FSMP, including distinct plant extracts, vitamins and minerals, and additional (antioxidative) compounds; (2) a dietary supplement only comprising vitamins and minerals and additional (antioxidative) compounds; and (3) a placebo containing only glucose. The study followed the CONSORT (Consol…

0301 basic medicinemedicine.medical_specialtyHealth (social science)NauseaBody waterDietary supplementMedicine (miscellaneous)AlcoholPlaceboDouble blind03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicinemedicine1506nutritional treatmentlcsh:RC620-627Original ResearchNutrition and Dieteticsbusiness.industryConsolidated Standards of Reporting TrialsIntervention studieslcsh:Nutritional diseases. Deficiency diseases030104 developmental biologychemistrymedicine.symptombusiness030217 neurology & neurosurgeryBMJ Nutrition, Prevention & Health
researchProduct

β2-Adrenoceptors and GRK2 as Potential Biomarkers in Patients With Chronic Pulmonary Regurgitation

2019

Pulmonary regurgitation (PR) is a frequent complication after repair of congenital heart disease. Three different GRK isoforms (GRK2, GRK5, and GRK3) and two β-adrenoceptors (β1-AR and β2-AR) are present in peripheral blood mononuclear cells (PBMC) and their expression changes as a consequence of the hemodynamic and neurohumoral alterations that occur in some cardiovascular diseases. Therefore, they could be useful as biomarkers in PR. A prospective study was conducted to describe the expression (TaqMan Gene Expression Assays) of β-ARs and GRKs in PBMC isolated (Ficoll® gradient) from patients with severe PR before and after pulmonary valve replacement and establish if this expression corre…

0301 basic medicinemedicine.medical_specialtyHeart diseaseGRK2HemodynamicsPulmonary regurgitationright ventricleGastroenterologyAsymptomaticPeripheral blood mononuclear cell03 medical and health sciences0302 clinical medicinepulmonary regurgitationPulmonary Valve ReplacementInternal medicineGene expressionmedicinePharmacology (medical)Prospective cohort studyβ2-adrenoceptorCongenital heart diseaseOriginal ResearchPharmacologybusiness.industrylcsh:RM1-950medicine.diseasecongenital heart diseaselcsh:Therapeutics. Pharmacology030104 developmental biologyPulmonary valve replacement030220 oncology & carcinogenesispulmonary valve replacementRight ventriclemedicine.symptomComplicationbusinessFrontiers in Pharmacology
researchProduct

PAI-1 4G-4G, MTHFR 677TT, V Leiden 506Q, and Prothrombin 20210A in Splanchnic Vein Thrombosis: Analysis of Individual Patient Data From Three Prospec…

2015

There are no univocal opinions on the role of genetic thrombophilia on splanchnic vein thrombosis (SVT). We defined genetic thrombophilia the presence of one of these thrombophilic genetic factors (THRGFs): PAI-1 4G-4G, MTHFR 677TT, V Leiden 506Q, and prothrombin 20210A.To evaluate the frequencies of these THRGFs in SVT patients, we analyzed individual data of 482 Caucasian patients, recruited from 2000 to 2014 in three prospective studies. SVT was defined as the presence of thrombosis of portal (PVT), mesenteric (MVT), splenic (SPVT), cava (CT), and hepatic vein (Budd Chiari syndrome, BCS). Pre-hepatic SVT (pre-HSVT) was defined as PVT with or without MVT/SPVT, without BCS. Post-hepatic SV…

0301 basic medicinemedicine.medical_specialtyHepatologybiologybusiness.industry030204 cardiovascular system & hematologymedicine.diseaseThrombophiliaGastroenterologyThrombosisSurgeryPortal vein thrombosis03 medical and health sciences030104 developmental biology0302 clinical medicineSplanchnic vein thrombosisInternal medicineMethylenetetrahydrofolate reductaseBudd–Chiari syndromebiology.proteinMedicineOriginal ArticlebusinessProspective cohort studyMyeloproliferative neoplasm
researchProduct

Age-Related Adaptations of Lower Limb Intersegmental Coordination During Walking

2019

Lower-limb intersegmental coordination is a complex component of human walking. Aging may result in impairments of motor control and coordination contributing to the decline in mobility inducing loss of autonomy. Investigating intersegmental coordination could therefore provide insights into age-related changes in neuromuscular control of gait. However, it is unknown whether the age-related declines in gait performance relates to intersegmental coordination. The aim of this study was to evaluate the impact of aging on the coordination of lower limb kinematics and kinetics during walking at a conformable speed. We then assessed the body kinematics and kinetics from gait analyses of 84 volunt…

0301 basic medicinemedicine.medical_specialtyHistologylcsh:Biotechnologylocomotor controlBiomedical EngineeringBioengineering02 engineering and technologyKinematicsbiomechanics03 medical and health sciencesGait (human)Physical medicine and rehabilitationlcsh:TP248.13-248.65medicineOriginal Researchbusiness.industryagingpanar covariationBiomechanicsMotor controlBioengineering and Biotechnology021001 nanoscience & nanotechnologyExplained variationbody regions030104 developmental biologymedicine.anatomical_structureGait analysisgait analysisAnkle0210 nano-technologybusinessRange of motionBiotechnologyFrontiers in Bioengineering and Biotechnology
researchProduct

Bergamot reduces plasma lipids, atherogenic small dense LDL, and subclinical atherosclerosis in subjects with moderate hypercholesterolemia: A 6 mont…

2016

Background: Some patients experience statin-induced side effects or prefer nutraceutical approaches for the treatment of dyslipidemia. This has led to a search for alternative therapeutic approaches for dyslipidemia management. In recent studies Citrus bergamia (known as Bergamot) juice was able to reduce serum levels of lipids. Such benefit may be attributed to high amounts of flavonoids contained in Bergamot fruit juice (neoeriocitrin, neohesperidin, naringin). The aim of the present study was to fully investigate the effects of a Bergamot extract on cardio-metabolic parameters, including plasma lipids, atherogenic lipoproteins and subclinical atherosclerosis. Methods: Eighty subjects (42…

0301 basic medicinemedicine.medical_specialtyHypercholesterolemiaBergamotCarotid IMT030204 cardiovascular system & hematology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineNeoeriocitrinMedicinePharmacology (medical)Prospective cohort studyNaringinOriginal ResearchLDL subclassesPharmacologyNeohesperidinbusiness.industryCholesterollcsh:RM1-950medicine.diseaseCardiovascular risklcsh:Therapeutics. Pharmacology030104 developmental biologyEndocrinologychemistryLow-density lipoproteinlipids (amino acids peptides and proteins)LDL subclassebusinessDyslipidemiaLipoprotein
researchProduct

TSH/IGF-1 Receptor Cross Talk in Graves' Ophthalmopathy Pathogenesis.

2016

AbstractContext:The TSH receptor (TSHR) is considered the main target of stimulatory autoantibodies in the pathogenesis of Graves' ophthalmopathy (GO); however, it has been suggested that stimulatory IGF-1 receptor (IGF-1R) autoantibodies also play a role.Objective:We previously demonstrated that a monoclonal stimulatory TSHR antibody, M22, activates TSHR/IGF-1R cross talk in orbital fibroblasts/preadipocytes obtained from patients with GO (GO fibroblasts [GOFs]). We show that cross talk between TSHR and IGF-1R, not direct IGF-1R activation, is involved in the mediation of GO pathogenesis stimulated by Graves' autoantibodies.Design/Setting/Participants:Immunoglobulins were purified from the…

0301 basic medicinemedicine.medical_specialtyLinsitinibEndocrinology Diabetes and MetabolismClinical Biochemistry030209 endocrinology & metabolismContext (language use)BiochemistryThyrotropin receptorReceptor IGF Type 1Graves' ophthalmopathyPathogenesis03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyInternal medicineCyclic AMPMedicineHumansHyaluronic AcidReceptorCells Culturedbusiness.industryBiochemistry (medical)AutoantibodyReceptors ThyrotropinReceptor Cross-TalkOriginal Articlesmedicine.diseaseGraves Ophthalmopathy030104 developmental biologyEndocrinologychemistryMonoclonalbusinessOrbitThe Journal of clinical endocrinology and metabolism
researchProduct

Adjuvant MUC vaccination with tecemotide after resection of colorectal liver metastases: a randomized, double-blind, placebo-controlled, multicenter …

2020

ABSTRACT Resection of colorectal liver metastases (CRLM) is a potential curative treatment for patients with metastatic colorectal cancer (mCRC) with liver-limited disease (LLD). Although long-term survival improved considerably within the last decades, high recurrence rates of 50-75% after resection remain a major challenge.Tecemotide (L-BLP25) is an antigen-specific cancer vaccine inducing immunity against mucin-1 (MUC1). The LICC trial aimed to improve survival in patients with mCRC after R0/R1 resection of CRLM. LICC was a binational, randomized, double-blind, placebo-controlled, multicenter phase 2 study including patients with R0/R1 resected CRLM without evidence of metastatic disease…

0301 basic medicinemedicine.medical_specialtyLung Neoplasmsmucin-1 (muc1)Colorectal cancermedicine.medical_treatmentImmunologyMedizinPlaceboCancer VaccinesGastroenterologyResectionDouble blind03 medical and health sciences0302 clinical medicineCarcinoma Non-Small-Cell LungGermanyInternal medicinemedicineHumansImmunology and AllergyRC254-282Original ResearchMembrane Glycoproteinsresection of colorectal liver metastasesbusiness.industryLiver NeoplasmsVaccinationNeoplasms. Tumors. Oncology. Including cancer and carcinogenscolorectal neoplasmsRC581-607medicine.diseasedigestive system diseasesVaccination030104 developmental biologyOncologyCurative treatment030220 oncology & carcinogenesistecemotide (l-blp25)TecemotideNeoplasm Recurrence LocalImmunologic diseases. AllergybusinessAdjuvantResearch Articleliver-limited diseaseOncoImmunology
researchProduct

Biotechnological Agents for Patients With Tumor Necrosis Factor Receptor Associated Periodic Syndrome-Therapeutic Outcome and Predictors of Response:…

2021

Objective: To describe the role of biotechnological therapies in patients with tumor necrosis factor receptor associated periodic syndrome (TRAPS) and to identify any predictor of complete response.Methods: Clinical, laboratory, and therapeutic data from 44 Caucasian TRAPS patients treated with biologic agents were retrospectively collected in 16 Italian tertiary Centers.Results: A total of 55 biological courses with anakinra (n = 26), canakinumab (n = 16), anti-TNF-α agents (n = 10), and tocilizumab (n = 3) were analyzed. A complete response was observed in 41 (74.5%) cases, a partial response in 9 (16.4%) cases and a treatment failure in 5 (9.1%) cases. The frequency of TRAPS exacerbation…

0301 basic medicinemedicine.medical_specialtyMedicine (General)Settore MED/16 - REUMATOLOGIAmedicine.drug_classtumor necrosis factor inhibitorsbiologic therapy interleukin-1 inhibitors personalized medicine tocilizumab tumor necrosis factor inhibitors tumor necrosis factor receptor-associated periodic syndromeinterleukin-1 inhibitorsGastroenterology03 medical and health scienceschemistry.chemical_compoundtocilizumab0302 clinical medicineTocilizumabR5-920Internal medicinemedicinebiologic therapyAdverse effecttumor necrosis factor receptor-associated periodic syndromeOriginal Research030203 arthritis & rheumatologyAnakinraProteinuriabiologymedicine.diagnostic_testbusiness.industryC-reactive proteinGeneral MedicineTumor necrosis factor receptor associated periodic syndromepersonalized medicineCanakinumab030104 developmental biologychemistryErythrocyte sedimentation ratebiology.proteinAutoinflammationCorticosteroidMedicinemedicine.symptombusinessmedicine.drugbiologic therapy; interleukin-1 inhibitors; personalized medicine; tocilizumab; tumor necrosis factor inhibitors; tumor necrosis factor receptor-associated periodic syndrome
researchProduct

Behavioral and clinical characteristics of people receiving medical care for HIV infection in an outpatient facility in Sicily, Italy

2016

Paola Di Carlo,1 Giuliana Guadagnino,1 Palmira Immordino,1 Giovanni Mazzola,2 Pietro Colletti,2 Ilenia Alongi,1 Lucia Adamoli,1 Francesco Vitale,1 Alessandra Casuccio1 1Department of Sciences for Health Promotion and Mother-Child Care “G D’Alessandro”, University of Palermo, 2Department of Medicinal Clinics and Emerging Diseases, “Paolo Giaccone” Polyclinic University Hospital, Palermo, Italy Aim: The authors examined a cohort of HIV-positive outpatients at the AIDS Center of Palermo University in Italy in order to identify factors related to the frequency of their visits to the outpatient facility for health care services.Methods: Two hundr…

0301 basic medicinemedicine.medical_specialtyMultivariate analysisSettore MED/17 - Malattie Infettivehard-to-reach groups030106 microbiologyHuman immunodeficiency virus (HIV)Medicine (miscellaneous)HIV Outpatient Servicemedicine.disease_causeSettore MED/42 - Igiene Generale E Applicata03 medical and health sciences0302 clinical medicineOutpatient facilityAmbulatory careAcquired immunodeficiency syndrome (AIDS)CD4+ T-cell countHealth careMedicine030212 general & internal medicinePharmacology Toxicology and Pharmaceutics (miscellaneous)Access to care; CD4+ T-cell count; Hard-to-reach groups; HIV infection; HIV outpatient service; Resource use; Social Sciences (miscellaneous); Medicine (miscellaneous); Health Policy; Pharmacology Toxicology and Pharmaceutics (miscellaneous)Original Researchaccess to carelcsh:R5-920business.industryHealth PolicyUnivariatemedicine.diseaseHIV infectionresource usePatient Preference and AdherenceEmergency medicineCohortbusinesslcsh:Medicine (General)Hard-to-reach groupSocial Sciences (miscellaneous)
researchProduct

Postoperative intestinal fistula in primary advanced ovarian cancer surgery

2021

Antoni Llueca,1– 3 Anna Serra,1– 3 Maria Teresa Climent,1,2 Karina Maiocchi,2,4 Alvaro Villarin,2,4 Katty Delgado,2,5 Josep Mari-Alexandre,6 Juan Gilabert-Estelles,6,7 Paula Carrasco,3 Blanca Segarra,8 Luis Gomez,2,4 Juan Jose Hidalgo,3 Javier Escrig,3 Manuel Laguna2,4 On behalf of the MUAPOS working group (Multidisciplinary Unit of Abdominal Pelvic Oncology Surgery1Department of Gynecology and Obstetrics, University General Hospital of Castellon, Castellón, Spain; 2Multidisciplinary Unit of Abdominal Pelvic Oncology Surgery (MUAPOS), University General Hospital of Castellon, Castellón, Spain; 3Department of Medicine, University Jaume I (UJI), Caste…

0301 basic medicinemedicine.medical_specialtyMultivariate analysiscomplicationsFistulalcsh:RC254-28203 medical and health sciences0302 clinical medicineintestinal fistulaMedicineIn patientintestinal leakageOriginal ResearchAdvanced ovarian canceradvanced ovarian cancer surgerybusiness.industrymedicine.diseaseDebulkinglcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensSurgeryBowel obstruction030104 developmental biologyOncologyCancer Management and Research030220 oncology & carcinogenesisConventional PCIPeritoneal Cancer Indexbusiness
researchProduct